Report Library
All Reports
CDK Inhibitors Infographic
February 10, 2015
Ibrance (palbociclib, PFE) became the first CDK inhibitor approved in the U.S. on February 3, 2015, when it was approved by the FDA for the
first-line treatment of locally advanced or metastatic, ER+/HER2- breast cancer. In this one-page infographic, we provide a general
overview of the current CDK inhibitor developmental landscape.
To download the infographic, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
To download the infographic, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: | Oncology |
| Indications Covered: | Castleman's Disease |
Additional Resources: